Latest Breaking News On - Retinal disorders - Page 1 : vimarsana.com

Electroretinography Market Poised for Remarkable Growth, to Surpass USD 109 7 Million by 2033, Enabl

Electroretinography Market Poised for Remarkable Growth, to Surpass USD 109 7 Million by 2033, Enabl
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkWelch allynAsia pacificLawrence johnCostruzione strumenti oftalmiciDevelopment activitiesImaging incExpansion of researchPrudour pvt ltdAdvancements in technologyDiopsys incKonan medical united states incTechnologies incGlobal electroretinography marketDiagnostic technologies

Prevent Blindness Ohio declares May as first-ever Inherited Retinal Disease Genetic Testing Awareness Month

Prevent Blindness Ohio declares May as first-ever Inherited Retinal Disease Genetic Testing Awareness Month
highlandcountypress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from highlandcountypress.com Daily Mail and Mail on Sunday newspapers.

United statesAmy pullesAdriann keveBen shabermanAlinav dumitrescuRachelle linNatario couserMariagrazia buttittaBrenda niccumJoy thomasDuke healthAlkeus pharmaceuticalsUniversity of iowa hospitalsScience communicationsFoundation fighting blindnessEye health at prevent blindness

Gene Therapies in Degenerative Retinal Disease Hold

Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME.

Spherix networkSpherix global insightsAdverum biotechnologiesGlobal insightsSpherix global insightGene therapyRetinal specialistsRetinal disordersGeographic atrophyMacular degeneration

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on October 27, 2023, from Atlas Special Opportuni

Region flamandeUnited statesMichael dillenMaryt conwayTom graneyAtlas special opportunitiesConway communicationsCompany annualEuronext brusselsBelgian transparencyRetinal disordersIopharmaceutical companyAtlas special opportunitiesStandard of care

Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program

EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”). On Septe

Region flamandeUnited statesMichael dillenMaryt conwayTom graneyConway communicationsFunding programAtlas special opportunitiesCompany annualUnconditional fundingallowing companyAchieve topline dataEuronext brusselsSubscription agreementRetinal disordersIopharmaceutical companyConvertible bonds